Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | hypothetical protein | 0.0045 | 0.4357 | 0.4709 |
Loa Loa (eye worm) | hypothetical protein | 0.0043 | 0.4024 | 0.4348 |
Trypanosoma brucei | PAB1-binding protein , putative | 0.0026 | 0.1315 | 0.5 |
Echinococcus granulosus | bromodomain adjacent to zinc finger domain | 0.0062 | 0.7332 | 1 |
Leishmania major | hypothetical protein, conserved | 0.0026 | 0.1315 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0074 | 0.9254 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.004 | 0.3611 | 0.3902 |
Loa Loa (eye worm) | PHD-finger family protein | 0.0022 | 0.0518 | 0.0559 |
Plasmodium vivax | ataxin-2 like protein, putative | 0.0026 | 0.1315 | 0.5 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.0026 | 0.1315 | 0.5 |
Echinococcus multilocularis | bromodomain adjacent to zinc finger domain | 0.0062 | 0.7332 | 1 |
Echinococcus multilocularis | fetal alzheimer antigen, falz | 0.0024 | 0.0851 | 0.0739 |
Schistosoma mansoni | hypothetical protein | 0.0022 | 0.0518 | 0.0242 |
Trypanosoma cruzi | PAB1-binding protein , putative | 0.0026 | 0.1315 | 0.5 |
Schistosoma mansoni | bromodomain containing protein | 0.0066 | 0.7956 | 1 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.0026 | 0.1315 | 0.5 |
Brugia malayi | hypothetical protein | 0.0026 | 0.1315 | 0.0059 |
Echinococcus granulosus | bromodomain adjacent to zinc finger domain | 0.0038 | 0.3186 | 0.4076 |
Schistosoma mansoni | acetyl-CoA C-acetyltransferase | 0.0024 | 0.0851 | 0.0679 |
Brugia malayi | Bromodomain containing protein | 0.004 | 0.3599 | 0.2673 |
Echinococcus granulosus | fetal alzheimer antigen falz | 0.0024 | 0.0851 | 0.0739 |
Echinococcus multilocularis | bromodomain adjacent to zinc finger domain | 0.0038 | 0.3186 | 0.4076 |
Toxoplasma gondii | LsmAD domain-containing protein | 0.0026 | 0.1315 | 0.5 |
Trypanosoma cruzi | PAB1-binding protein , putative | 0.0026 | 0.1315 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0026 | 0.1315 | 0.1421 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.